Reinforcement Learning Drug Discovery via 3D Scaffold Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery techniques are intuition-driven and hampered by slow iterative design-test cycles due to computational challenges, limiting the ability to efficiently design molecules that bind tightly and specifically to target proteins.
Innovation Solution
A computing system employing a generative machine learning model with reinforcement learning, using a three-dimensional representation of molecules and proteins to iteratively add atoms and evaluate binding criteria, optimizing molecular properties such as activity, binding affinity, and synthetic accessibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional intuition-driven drug discovery methods are used, then expert chemist expertise is leveraged, but the process is slow and limited by human expertise
Solution Approach 1:
The patent replaces the mechanical system of human chemist intuition and manual molecular design with an automated reinforcement learning system. The RL agent autonomously generates molecular structures, evaluates binding affinity through deep neural networks, and iterates design cycles without human intervention, substituting human cognitive processes with computational algorithms that operate at machine speed
Solution Approach 2:
The reinforcement learning system performs self-service by autonomously completing the entire drug discovery workflow. The agent generates molecules, evaluates their binding affinity to target proteins, modifies structures based on feedback, and repeats the cycle independently without requiring human chemists to manually design and test each candidate
2Manufacturing precision
If iterative design-test cycles are performed manually, then molecular optimization can be achieved, but the cycles are slow due to computational challenges
Solution Approach 1:
The patent substitutes manual computational evaluations with automated deep neural network models that predict binding affinity in seconds. The RL agent receives immediate feedback from the neural network evaluator, enabling rapid iterative cycles where molecules are generated, evaluated, and modified without the time-consuming computational bottlenecks of traditional methods
Solution Approach 2:
The reinforcement learning system enables continuous iterative optimization where the agent constantly generates and evaluates molecular candidates in an unbroken loop. Unlike manual cycles that require discrete human intervention steps, the automated system continuously refines molecular structures based on binding affinity feedback, maintaining productive action without interruption
3Measurement precision
If three-dimensional modeling is used for molecular evaluation, then binding affinity can be accurately assessed, but computational complexity increases
Solution Approach 1:
The patent replaces complex manual computational chemistry calculations with trained deep neural networks that have learned the complexities of three-dimensional protein-ligand interactions during pre-training. The neural networks automatically handle the computational burden of 3D modeling, providing accurate binding affinity predictions without requiring the user to manage complex computational systems
Data Source
AI summary
Reinforcement learning is coupled to a deep generative model based on a three-dimensional scaffold model to generate drug candidates targeting a particular protein, building up atom or functional groups from a starting core scaffold. A reward function can use parallel graph neural network models and take the particular protein into account when calculating reward based on criteria such as binding, synthetic accessibility, and the like. In an agent-critic reinforcement learning model, the agent learns to build molecules in three-dimensional space while optimizing the criteria.